Crohn's disease: open trials in Serbia

9 open trials have a site in Serbia. Registry data; only the trial team decides who can take part.

NCT06226883
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 2 · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Clinical hospital center Bezanijska Kosa, Belgrade · Zvezdara University Medical Center, Belgrade · Clinical Center Dr Dragisa Misovic Dedinje, Belgrade · General Hospital Leskovac, Leskovac · General Hospital Uzice, Užice · General Hospital - Djordje Joanovic, Zrenjanin
Registry updated 2026-11-04
NCT06430801
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Clinical Hospital Center Dragisa Misovic (Site 1906), Belgrade · Clinical Hospital Center Zvezdara-Gastroenterology and hepatology Department (Site 1903), Belgrade · University Medical Center "Bezanijska kosa"-Gastroenterology and hepatology (Site 1900), Belgrade · Clinical Center Kragujevac (Site 1904), Kragujevac · Zemun Medical Centre (Site 1910), Zemun · General Hospital "Djordje Joanovic" (Site 1905), Zrenjanin
Registry updated 2026-11-02
NCT07683325
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Trial Treatment · Phase 2 · Agomab Spain S.L.U.
Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje', Belgrade · Clinical Hospital Center Zvezdara (CHCZ), Belgrade · Clinical hospital center Bezanijska Kosa, Belgrade
Registry updated 2026-10-29
NCT07184931
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Belgrade · Belgrade · Belgrade · Belgrade · Belgrade · Niš
Registry updated 2026-10-21
NCT07184944
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Sanofi
Belgrade
Registry updated 2026-10-21
NCT06819878
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Trial Treatment · Phase 3 · Hoffmann-La Roche
University Hospital Medical Center Zvezdara, Belgrade · Clinical Hospital Center Zemun, Belgrade · University Hospital Medical Center Bezanijska Kosa, Belgrade · University Hospital Center Dr Dragisa Misovic - Dedinje, Belgrade · Clinical Center of Vojvodina, Novi Sad · General Hospital - Djordje Joanovic, Zrenjanin
Registry updated 2026-10-16
NCT06405087
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Trial Treatment · Phase 3 · Takeda
University Children's Clinic, Belgrade · Institute for Children and Youth Health Care of Vojvodina, Novi Sad
Registry updated 2026-10-09
NCT06548542
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Trial Treatment · Phase 2 · AbbVie
Clinical Hospital Center Bezanijska Kosa /ID# 265604, Belgrade · Military Medical Academy /ID# 267452, Belgrade · Clinical Hospital Center Zvezdara /ID# 265605, Belgrade · Clinical Hospital Center Dr. Dragisa Misovic - Dedinje /ID# 265607, Belgrade · Leskovac General Hospital /ID# 265606, Leskovac · University Clinical Center Vojvodina /ID# 265603, Novi Sad · General Hospital Djordje Joanovic /ID# 266040, Zrenjanin
Registry updated 2026-09-25
NCT06100289
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Trial Treatment · Phase 3 · Takeda
Mother and child helath care Institute of Serbia dr Vukan Cupic, Belgrade · University Children's Hospital, Belgrade · Institute for Childand YouthHealth Care of Vojvodina, Novi Sad
Registry updated 2026-08-03

All Crohn's disease trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error